Q-omics provides the consensus-scored NOMO3 profile across patient tissues and cancer cell-line models. NOMO3 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, NOMO3 is differentially expressed in 8, with the highest sampling consensus in LIHC. Additionally, NOMO3 RNA expression shows 17,739 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight KIRC, LIHC, and THYM as cancer lineages where NOMO3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for NOMO3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes NOMO3 survival associations across molecular data types. NOMO3 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (3) and mass-spec protein abundance (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible NOMO3 RNA expression–survival associations across cancer types. High NOMO3 expression shows unfavorable associations in ESCA, LUSC, LUAD and KIRP, but favorable associations in KIRC and LGG. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .007). Together, the overview and detailed table identify KIRC as the clearest survival context for NOMO3 RNA expression.
This table summarizes NOMO3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8, while mass-spec protein shows differences in 7. The strongest signals are observed in LIHC for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for NOMO3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. NOMO3 shows higher tumor expression in LIHC, HNSC, BRCA, CHOL, STAD and READ. The LIHC box plot shows higher NOMO3 RNA expression in tumor versus normal tissue (log2 FC = +0.622, t-test p < 0.001).
This table shows molecular features associated with NOMO3 in patient tissues and cancer cell lines. In patient samples, NOMO3 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, NOMO3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LARGE_INTESTINE, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Lymphoma and STOMACH.
